Niagen Bioscience is trading at $2.93, up 9.33% in pre-market, with broader market gains potentially supporting the move; no company-specific catalyst has surfaced for October 2.

  • The latest reported company news was an October 1 brand campaign launch, which does not establish a reason for the move.
  • Supplied context shows the S&P 500 up 0.85% and Nasdaq up 1.27%; biotech sector context is negative, with XBI down 2.01%, so it does not explain the gain.